BioAgilytix is a leading provider of contract research services, specializing in large molecule bioanalytical testing to support the biopharmaceutical industry.
Bioanalytical testing services for large molecule drugs.
Approx. $0.3 billion (2024 estimate).
Specialized bioanalytical services, including immunoassays, biomarker analysis, and other laboratory services supporting the development of biopharmaceuticals.
BioAgilytix continues to expand its testing capabilities, particularly in the areas of cell and gene therapies, as well as its international presence.
Eurofins Scientific is a global group offering laboratory services in the fields of food, environment, pharmaceuticals, and biotechnology.
Laboratory services for life sciences, including testing and analysis in food safety, environmental sciences, and pharmaceutical R&D.
$5.6 billion (2024 estimate).
A wide range of laboratory services, including analytical testing, clinical diagnostics, and biotechnology research and development services.
Eurofins has continued to grow through acquisitions, expanding its capabilities in clinical diagnostics and pharmaceutical testing.
Precision for Medicine provides a range of services aimed at improving the precision of clinical trials and drug development, with a focus on oncology, immunology, and rare diseases.
Precision clinical trials and personalized medicine services for the biopharmaceutical industry.
$0.5 billion (2024 estimate).
Services in clinical trials, laboratory testing, and biomarker discovery, supporting personalized medicine development in therapeutic areas like oncology and immunology.
Precision for Medicine has been enhancing its services in genomic testing and biomarkers, aiming to advance personalized medicine for clinical trials.
Illumina is a global leader in DNA sequencing and array-based technologies, supporting genetic analysis for research, diagnostics, and drug development.
DNA sequencing systems, gene expression analysis tools, and genomic testing products.
$5.1 billion (2024 estimate).
High-throughput DNA sequencing platforms, reagents, and bioinformatics tools to enable genomic research and personalized healthcare.
Illumina continues to lead in next-generation sequencing technologies, with ongoing innovations in genomic testing for personalized medicine and clinical diagnostics.
Bio-Rad Laboratories is a multinational biotechnology company that develops and manufactures products for life science research and clinical diagnostics.
Diagnostic and research products, including immunoassays and PCR-based systems.
$2.7 billion (2024 estimate).
Products for laboratory diagnostics, research, and clinical testing, including life science reagents, PCR systems, and protein analysis tools.
Bio-Rad continues to innovate in clinical diagnostics, with a focus on molecular diagnostics and next-generation research tools.
Altasciences is a contract research organization (CRO) that provides services for the pharmaceutical and biotechnology industries, specializing in early-stage drug development.
Early-stage drug development services, clinical trials, and laboratory services.
Approx. $0.15 billion (2024 estimate).
Preclinical and clinical development services, including toxicology, clinical trials, and laboratory services aimed at advancing drug discovery.
Altasciences is expanding its global presence and capabilities in clinical trials and preclinical testing, especially in the areas of early-stage drug development.
QPS is a global contract research organization (CRO) providing preclinical and clinical research services for the pharmaceutical, biotechnology, and medical device industries.
Preclinical and clinical research services for drug development.
$0.1 billion (2024 estimate).
A broad range of preclinical and clinical research services, including bioanalytical testing, toxicology studies, clinical trial management, and more.
QPS has been expanding its capabilities in clinical trials and regulatory affairs, focusing on providing comprehensive services for drug development.
SpinoS Life Science is a biotechnology company focused on providing services in clinical trials, R&D, and laboratory testing, particularly in the field of precision medicine.
Clinical trial services and precision medicine testing.
Approx. $0.02 billion (2024 estimate).
Clinical trial management services and R&D in precision medicine, focusing on innovative therapies and treatments for various diseases.
SpinoS Life Science is increasing its focus on precision medicine and genetic testing in clinical trials, aiming to support the development of targeted therapies.
IntoxLab provides laboratory testing services specializing in alcohol and drug testing for forensic, clinical, and workplace environments.
Alcohol and drug testing services for clinical and forensic purposes.
Approx. $0.01 billion (2024 estimate).
Laboratory services for toxicology testing, focusing on alcohol and drug testing in various industries and environments.
IntoxLab is enhancing its forensic testing services, focusing on expanding its offerings in clinical toxicology.
Thermo Fisher Scientific is a leading global provider of laboratory instruments, chemicals, reagents, and services for the healthcare, research, and industrial markets.
Laboratory instruments, reagents, diagnostics, and biotechnology products.
$40.0 billion (2024 estimate).
A wide range of scientific services and products, including laboratory reagents, instruments, clinical diagnostics, and drug discovery technologies.
Thermo Fisher continues to invest in expanding its research and diagnostics capabilities, including acquisitions to strengthen its life sciences and clinical research segments.
Syneos Health is a global biopharmaceutical solutions organization that provides integrated biopharmaceutical solutions for clinical trials, regulatory services, and commercialization.
Clinical trials and commercialization services for biopharmaceutical companies.
$2.6 billion (2024 estimate).
Integrated solutions for the entire drug development lifecycle, from clinical trials to regulatory services and commercialization.
Syneos Health is enhancing its global capabilities in drug development and commercialization, with a focus on accelerating the delivery of therapies to market.
The global bioanalytical testing services market size is calculated at USD 4.54 billion in 2025, grew to USD 5.25 billion in 2026, and is projected to reach around USD 18.66 billion by 2035. The market is expanding at a CAGR of 15.54% between 2026 and 2035.
Company Overview : Charles River Laboratories is a leading global contract research organization (CRO) providing essential products and services to help pharmaceutical, biotechnology, medical device companies, and academic/government institutions accelerate their research and drug development efforts. It is a full-service, early-stage CRO.
Corporate Information (Headquarters, Year Founded, Ownership Type)
Key Milestones/Timeline
Business Segments/Divisions
Key Offerings
End-Use Industries Served
Key Developments and Strategic Initiatives
Mergers & Acquisitions
Partnerships & Collaborations
Continued strategic focus on integrated service models, offering clients end-to-end support from discovery to commercial manufacturing.
Product Launches/Innovations
Capacity Expansions/Investments
Regulatory Approvals
Maintains key global accreditations and compliance standards, including FDA and EMA compliance, and AAALAC International Accreditation.
Distribution channel strategy
Primarily direct sales through dedicated global sales and scientific teams, emphasizing integrated, end-to-end solutions, particularly for early-stage development clients.
Technological Capabilities/R&D Focus
Core Technologies/Patents
Research & Development Infrastructure
Extensive global network of state-of-the-art research and testing facilities.
Innovation Focus Areas
Competitive Positioning
Strengths & Differentiators
Market Presence & Ecosystem Role
SWOT Analysis
Recent News and Updates
Press Releases
Industry Recognitions/Awards
Information not explicitly found in recent, concise news snippets, but generally recognized as a leading global CRO.
Company Overview: Labcorp Drug Development, formerly Covance, is a global contract research organization providing a full suite of drug development services, from preclinical testing and clinical trials to commercialization. It is a key segment of the larger Labcorp life sciences company.
Key Milestones/Timeline
Business Segments/Divisions
Key Offerings
End-Use Industries Served
Key Developments and Strategic Initiatives
Mergers & Acquisitions
Partnerships & Collaborations
Product Launches/Innovations
Capacity Expansions/Investments
Regulatory Approvals
Distribution channel strategy
Leverages its extensive network of patient-service centers and laboratories for diagnostics, while the Drug Development segment utilizes a direct sales model for CRO services to biopharma clients.
Technological Capabilities/R&D Focus
Core Technologies/Patents
Research & Development Infrastructure
Extensive global laboratory infrastructure, including its central lab and specialized testing facilities.
Innovation Focus Areas
Competitive Positioning
Strengths & Differentiators
Market presence & ecosystem role
SWOT Analysis
Recent News and Updates
Press Releases
Industry Recognitions/Awards
Information not explicitly found in recent, concise news snippets, but generally recognized as a global leader in laboratory and drug development services.
Top Companies & Their Offerings in the Bioanalytical Testing Services Market
Partner with our experts to explore the Bioanalytical Testing Market at sales@towardshealthcare.com
